Stock Performance Review on Medical Labs & Research Industry -- PAREXEL, China Cord Blood, ICON, and PRA Health Sciences

Wednesday, July 19, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 19, 2017 /PRNewswire/ --

If you want a Stock Review on PRXL, CO, ICLR, or PRAH then come over to

and sign up for your free customized report today. On Tuesday, the NASDAQ Composite ended the day at 6,344.31, up 0.47%; the Dow Jones Industrial Average edged 0.25% lower, to finish at 21,574.73; and the S&P 500 closed at 2,460.61, marginally gaining
0.06%. US markets saw a mixed session as 4 sectors closed in green, 4 sectors finished in red, and 1 sector ended flat for the day. has initiated research reports on the following Medical Laboratories & Research stocks: PAREXEL International Corp. (NASDAQ: PRXL), China Cord Blood Corp. (NYSE: CO), ICON PLC (NASDAQ: ICLR), and PRA Health Sciences Inc. (NASDAQ: PRAH). Daily Stock Tracker published comprehensive and free research reports on these stocks today at:


Waltham, Massachusetts headquartered PAREXEL International Corp.'s stock finished Tuesday's session 0.24% lower at $87.35 with a total trading volume of 810,308 shares. The Company's shares have advanced 42.80% in the previous three months, 35.41% over the last twelve months, and 32.91% since the start of this year. The stock is trading above its 50-day moving and 200-day moving averages by 5.86% and 26.99%, respectively. Additionally, shares of PAREXEL, which provides clinical research and logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide, have a Relative Strength Index (RSI) of 72.01.

On June 20th, 2017, research firm Raymond James upgraded the Company's stock rating from 'Underperform' to 'Market Perform'. PRXL complete research report is just a click away and free at:

China Cord Blood 

On Tuesday, shares in Central, Hong Kong-based China Cord Blood recorded a trading volume of 408,456 shares. The stock ended the session 0.29% lower at $10.23. The Company's shares have advanced 12.05% in the last month, 36.40% in the previous three months, 87.71% over the past twelve months, and 67.16% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 17.19% and 58.10%, respectively. Moreover, shares of China Cord Blood, which together with its subsidiaries, primarily provides umbilical cord blood storage and ancillary services in the People's Republic of China, have an RSI of 64.35. The complimentary report on CO can be downloaded at:


Dublin, Ireland headquartered ICON PLC's shares closed the day 0.45% lower at $98.77. The stock recorded a trading volume of 150,805 shares. The Company's shares have gained 28.21% over the previous three months, 36.78% in the last twelve months, and 31.34% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.92% and 18.43%, respectively. Additionally, shares of ICON, which provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the US, and internationally, have an RSI of 61.56.

On June 29th, 2017, research firm Jefferies upgraded the Company's stock rating from 'Hold' to 'Buy'. Sign up for your complimentary research report on ICLR at:

PRA Health Sciences 

Shares in Raleigh, North Carolina headquartered PRA Health Sciences Inc. finished 0.70% lower at $75.00. The stock recorded a trading volume of 315,955 shares. The Company's shares have advanced 15.56% in the previous three months, 68.31% over the last twelve months, and 36.07% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.06% and 21.54%, respectively. Furthermore, shares of PRA Health Sciences, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, have an RSI of 52.60.

On June 26th, 2017, research firm Bank of America/ Merrill initiated a 'Buy' rating on the Company's stock, with a target price of $89 per share. Get free access to your research report on PRAH at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store